TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance

BACKGROUND & AIMS: Identifying novel and actionable targets in hepatocellular carcinoma (HCC) remains an unmet medical need. TAK1 was originally identified as a transforming growth factor-β–activated kinase and was further proved to phosphorylate and activate numerous downstream targets and prom...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Shunjie, Ji, Lin, Tao, Liye, Pan, Yu, Lin, Zhongjie, Wan, Zhe, Pan, Haoqi, Zhao, Jie, Cai, Liuxin, Xu, Junjie, Cai, Xiujun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350196/
https://www.ncbi.nlm.nih.gov/pubmed/33962073
http://dx.doi.org/10.1016/j.jcmgh.2021.04.016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350196/
https://www.ncbi.nlm.nih.gov/pubmed/33962073
http://dx.doi.org/10.1016/j.jcmgh.2021.04.016

Ejemplares similares